预约演示
更新于：2025-04-17
Apixaban
阿哌沙班
更新于：2025-04-17
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C25H25N5O4 |
InChIKeyQNZCBYKSOIHPEH-UHFFFAOYSA-N |
CAS号503612-47-3 |
关联
417
项与 阿哌沙班 相关的临床试验NCT06474182
Comparison of the Effects of Prophylactic Administration of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma and Patients Undergoing a Surgery for Total Knee Replacement
TCTR20250307002
Comparative effectiveness and safety of branded and generic apixaban among patients with atrial fibrillation in Thailand
CTR20250835
LN2227餐后人体生物等效性研究
100 项与 阿哌沙班 相关的临床结果
登录后查看更多信息
100 项与 阿哌沙班 相关的转化医学
登录后查看更多信息
100 项与 阿哌沙班 相关的专利（医药）
登录后查看更多信息
6,906
项与 阿哌沙班 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany
Article
作者: Dworatzek, Elke ; Kongnakorn, Thitima ; Duan, Cecilia ; Shah, Anshul ; Kisser, Agnes ; Subash, Rupesh ; Hines, Dionne M. ; Hagan, Melissa ; Zhang, Michelle
AIMS:
Direct-acting oral anticoagulants (DOACs) have emerged as the preferred treatment for nonvalvular atrial fibrillation (NVAF). However, evidence concerning the economic outcomes of DOAC switching remains limited. This study aimed to assess the economic outcomes of DOAC switching in the US and Germany, two countries with a high AF prevalence and DOAC utilization.
METHODS:
A decision model was developed to assess the incidence and cost of stroke/systemic embolism (SE) and major bleeding (MB) associated with switching from apixaban to rivaroxaban in patients with NVAF. The model compared two scenarios: continuers (patients continuing apixaban) and switchers (patients switching from apixaban to rivaroxaban). Model inputs on clinical event rates were sourced from a published real-world study, cost inputs were from a standard costing database and published literature. The analysis was conducted over a 1-year time horizon from US Medicare fee-for-service and German public healthcare payer perspectives.
RESULTS:
Over one year, 47,036 patients among a hypothetical plan size of 1,000,000 US Medicare fee-for-service members and 1,019,079 patients among the German adult population size of 70,107,122 were estimated to be treated for NVAF with apixaban. Switching all patients from apixaban to rivaroxaban resulted in 1,498 and 32,447 additional clinical events (stroke/SE and MB) and deaths in the US and Germany, respectively, compared to continuing with apixaban. This led to a total incremental cost of $17.3 million and €153 million from Medicare fee-for-service and German public healthcare perspectives, respectively.
LIMITATIONS:
The incidence and hazard ratios of clinical events informing this analysis were based on a US commercial and Medicare Advantage population and may not be generalizable to other populations.
CONCLUSIONS:
Switching from apixaban to rivaroxaban was associated with increased clinical events, deaths, and higher medical care costs, potentially representing a less favorable strategy economically compared to continuing apixaban among patients with NVAF.
2025-05-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Simultaneous quantification of eighteen therapeutic oral anticoagulants, rodenticides, and antiplatelet agents by LC-MS/MS and its application in post-mortem forensic cases
Article
作者: Bidat, Carolyne ; Feliu, Catherine ; Duband, Sébastien ; Escal, Jean ; Dellinger, Sandrine ; Hodin, Sophie ; Drague, Angélique ; Delavenne, Xavier
Anticoagulants and antiplatelet agents, which interfere with blood coagulation, can lead to fatal bleeding. Moreover, their widespread use as drugs or rodenticides poses a high risk of accidental or intentional poisoning. Therefore, quantifying these substances is essential in forensic investigations. This research aimed to develop and validate a liquid chromatography-tandem mass spectrometry method capable of quantifying eighteen anticoagulant or antiplatelet compounds (apixaban, rivaroxaban, dabigatran, warfarin, acenocoumarol, fluindione, brodifacoum, bromadiolone, difenacoum, difethialone, chlorophacinone, coumatetralyl, flocoumafen, acetylsalicylic acid, clopidogrel, dipyridamole, ticagrelor, and ticlopidine) in a single run with simple sample preparation. The method was validated according to the FDA recommendations for all compounds, with an eight-min run time in human whole blood, the gold standard in toxicological forensic investigation. The method was also validated for therapeutic compounds and most rodenticides in bile and vitreous humor. Following validation, the method was applied to seven forensic cases with a known history of anticoagulant or antiplatelet agent use to prove the validity of the method. This method provides a valuable tool for legal contexts where precise determination of anticoagulant compound presence and concentration is required.
2025-05-01Journal of Vascular Surgery-Venous and Lymphatic Disorders
Continuation of anticoagulation through ambulatory phlebectomy does not impact postoperative bleeding risk
Article
作者: Li, Ya-Huei ; Gallagher, James ; Orosco, Emily ; Cleary, Colin M ; Gifford, Edward D ; Ayach, Mouhanad ; Davoudi, Kaveh ; Wrana, Kristy ; Bailey, Allison ; Aitcheson, Elizabeth ; Shah, Parth
OBJECTIVES:
Chronic anticoagulation for atrial fibrillation, a history of venous thromboembolism, and after heart valve replacement is often stopped or bridged for surgery. Our institutional practice is to continue anticoagulation through ambulatory phlebectomy (AP) procedures. As such, we aimed to compare postprocedure bleeding and major adverse events in patients on anticoagulation who received AP compared with patients not on anticoagulation.
METHODS:
We included all patients who required AP from January 2016 to February 2023. Given the low frequency of chronic anticoagulation during the study period, as defined as patients on anticoagulation ≥30 days before index procedure and not held through the procedure, a propensity score match of 16 demographic parameters was performed to better match patients. After propensity matching, we compared the frequency and quality of postprocedural bleeding (none, incisional, large volume), extent of postprocedural ecchymosis (none, minimal, moderate, significant), and pain (minimal, moderate, severe) on follow-up examination with a provider. Thirty-day emergency department (ED) visits and major adverse cardiac events were also recorded for each patient. Continuous variables were compared using independent t tests or Mann-Whitney U tests, and categorical variables were compared using a χ2 or Fisher's exact test.
RESULTS:
In total, 1853 patients received AP from four outpatient offices during the study period, 101 (5.5%) of whom were on chronic anticoagulation. Seventy patients for each group were propensity score matched in key demographics including age, gender, body mass index, Clinical-Etiology-Anatomy-Pathophysiology classification, prior vein procedures, concomitant laser procedures, number of phlebectomies performed, and comorbidities like history of deep vein thrombosis, pulmonary embolism, and peripheral arterial disease. There were no intraoperative major bleeding events. Patients on chronic anticoagulation were not more likely to have increased postprocedural bleeding (2.9% vs 0%; P > .05), significant ecchymosis (4.5% vs 1.5%; P = .671), severe pain on follow-up (1.4% vs 0%; P > .05), or increased likelihood of postprocedural cellulitis (1.4% vs 0%; P > .05). There were no instances of 30-day ED visits or major adverse cardiac events. Within patients on anticoagulation, use of rivaroxaban (8%) had higher incidence of bleeding than those on apixaban or warfarin (0%); however, these findings were not significant.
CONCLUSIONS:
AP while continuing chronic anticoagulation did not result in an increased rate of bleeding, ED visits, or major adverse events. It is likely safe to continue anticoagulation throughout these outpatient procedures.
100 项与 阿哌沙班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 复发性深静脉血栓形成 | 欧盟 | 2020-07-23 | |
| 复发性深静脉血栓形成 | 冰岛 | 2020-07-23 | |
| 复发性深静脉血栓形成 | 列支敦士登 | 2020-07-23 | |
| 复发性深静脉血栓形成 | 挪威 | 2020-07-23 | |
| 血栓形成 | 中国 | 2013-01-22 | |
| 缺血性卒中 | 日本 | 2012-12-25 | |
| 全身性栓塞 | 澳大利亚 | 2011-07-21 | |
| 心房颤动 | 欧盟 | 2011-05-18 | |
| 心房颤动 | 冰岛 | 2011-05-18 | |
| 心房颤动 | 列支敦士登 | 2011-05-18 | |
| 心房颤动 | 挪威 | 2011-05-18 | |
| 栓塞 | 欧盟 | 2011-05-18 | |
| 栓塞 | 冰岛 | 2011-05-18 | |
| 栓塞 | 列支敦士登 | 2011-05-18 | |
| 栓塞 | 挪威 | 2011-05-18 | |
| 肺栓塞 | 欧盟 | 2011-05-18 | |
| 肺栓塞 | 冰岛 | 2011-05-18 | |
| 肺栓塞 | 列支敦士登 | 2011-05-18 | |
| 肺栓塞 | 挪威 | 2011-05-18 | |
| 脑卒中 | 欧盟 | 2011-05-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肢体威胁性缺血 | 临床3期 | 巴西 | 2020-01-09 | |
| 脑梗塞 | 临床3期 | 美国 | 2018-12-19 | |
| 脑梗塞 | 临床3期 | 美国 | 2018-12-19 | |
| 认知功能障碍 | 临床3期 | 美国 | 2018-12-19 | |
| 认知功能障碍 | 临床3期 | 美国 | 2018-12-19 | |
| 基底细胞癌 | 临床3期 | 奥地利 | 2018-10-11 | |
| 基底细胞癌 | 临床3期 | 比利时 | 2018-10-11 | |
| 基底细胞癌 | 临床3期 | 加拿大 | 2018-10-11 | |
| 基底细胞癌 | 临床3期 | 法国 | 2018-10-11 | |
| 基底细胞癌 | 临床3期 | 希腊 | 2018-10-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,015 | (Active Agent: Apixaban) | 積膚齋艱蓋齋網淵壓繭 = 觸鹽獵構鹽獵憲廠鹽觸 壓製選憲糧選襯壓願窪 (艱窪顧鏇鏇憲壓糧網顧, 鑰觸憲鏇簾衊淵齋鏇餘 ~ 鏇繭鹽觸鏇襯襯蓋糧鹽) 更多 | - | 2025-04-09 | ||
(Active Control: Aspirin) | 積膚齋艱蓋齋網淵壓繭 = 衊積範壓壓醖夢網構齋 壓製選憲糧選襯壓願窪 (艱窪顧鏇鏇憲壓糧網顧, 夢網範願齋餘鹽繭鹹膚 ~ 艱夢鬱鬱醖網築糧壓窪) 更多 | ||||||
临床3期 | 1,291 | Placebo (Placebo) | 鹽艱鹹願糧顧衊鹹餘齋 = 醖糧簾襯遞窪範選遞襯 艱範簾繭餘憲願醖夢繭 (廠獵獵鹽鏇艱齋鹹積願, 廠壓糧積願製構襯構繭 ~ 顧餘網範齋襯廠築廠築) 更多 | - | 2025-02-25 | ||
(Apixaban) | 鹽艱鹹願糧顧衊鹹餘齋 = 膚壓積夢鏇鏇襯遞願窪 艱範簾繭餘憲願醖夢繭 (廠獵獵鹽鏇艱齋鹹積願, 範襯鹹餘築繭艱艱築鑰 ~ 築艱簾積襯衊範觸製簾) 更多 | ||||||
临床2期 | 48 | 願築繭艱鹽築夢襯壓鏇(夢餘鏇膚艱衊製餘製艱) = 在监管机构认可的范围(80-125%)内 餘糧醖獵艱廠鹹壓鑰製 (醖鏇餘艱願艱艱襯鑰鹽 ) 更多 | 积极 | 2025-02-18 | |||
临床4期 | 4,614 | Apixaban + Placebo | 鹽遞顧鑰獵廠艱齋繭廠(鏇淵蓋獵鬱築鹽廠獵壓) = 襯製簾顧膚選壓築壓願 窪鏇選衊鹹鑰構廠糧積 (廠膚構衊鏇艱範齋製繭, 28) | 不佳 | 2025-02-01 | ||
鹽遞顧鑰獵廠艱齋繭廠(鏇淵蓋獵鬱築鹽廠獵壓) = 膚壓夢艱選鏇鹹鏇糧顧 窪鏇選衊鹹鑰構廠糧積 (廠膚構衊鏇艱範齋製繭, 29) | |||||||
N/A | - | 築網製鹹繭壓積憲膚淵(鹽艱構鹹獵鹽鑰繭製範) = 積廠網網鬱鑰獵廠築夢 蓋淵鑰製糧衊鬱壓膚選 (觸廠鏇憲醖構齋獵鬱鹽, 0.29 ~ 0.81) 更多 | 积极 | 2025-01-30 | |||
N/A | - | (Favorable Polygenic Profile) | 繭選鑰範鹹簾窪網範廠(夢淵膚遞簾鹽鏇範艱網) = cumulative incidence:1.5%[95%CI:1.00–2.20] 鬱糧餘遞顧顧夢積範製 (網遞襯齋製構積網夢鑰 ) | 积极 | 2025-01-30 | ||
(Adverse Polygenic Profile) | |||||||
N/A | - | 襯願窪鑰繭艱鹽艱艱壓(願繭製構網製簾醖製憲): HR = 0.92 (95% CI, 0.83 ~ 1.03), P-Value = 0.13 更多 | 积极 | 2025-01-30 | |||
Standard of Care (SOC) | |||||||
N/A | - | Prophylactic dose apixaban (2.5 mg twice daily) | 壓願簾淵遞積鏇簾鑰蓋(築遞製襯鑰積壓範壓積) = 壓繭顧衊簾夢積網繭艱 選鑰夢廠觸淵製廠膚齋 (憲醖鏇膚鏇選窪鏇鹹願, 6.4 ~ 12.6) 更多 | - | 2024-12-08 | ||
Therapeutic dose apixaban (5 mg twice daily) | 壓願簾淵遞積鏇簾鑰蓋(築遞製襯鑰積壓範壓積) = 範衊糧衊艱艱衊獵醖鏇 選鑰夢廠觸淵製廠膚齋 (憲醖鏇膚鏇選窪鏇鹹願, 14.8 ~ 19.8) 更多 | ||||||
N/A | - | 齋糧蓋膚齋願鬱獵觸願(積觸範膚窪鏇齋憲憲遞) = 鏇糧願蓋衊獵夢顧艱齋 憲選鹽鹽艱範選廠網鬱 (夢糧齋餘觸壓觸積醖鑰, ±5.4) 更多 | - | 2024-12-08 | |||
临床4期 | 229 | 壓艱襯糧糧壓膚願鏇範(鑰繭鹹簾夢選選齋壓築) = 鬱顧齋鹽鹽製憲繭壓顧 壓壓範鹽範齋壓獵獵範 (窪醖構膚築遞範簾構繭, 0.8 ~ 6.7) 更多 | 积极 | 2024-12-07 | |||
Standard of Care (VKA, LMWH, UFH) | 壓艱襯糧糧壓膚願鏇範(鑰繭鹹簾夢選選齋壓築) = 顧遞夢鏇餘選蓋壓範構 壓壓範鹽範齋壓獵獵範 (窪醖構膚築遞範簾構繭, 0.2 ~ 9.9) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用